Literature DB >> 12588335

Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.

N P Brenwald1, P Appelbaum, T Davies, M J Gill.   

Abstract

Fluoroquinolone resistance in pneumococci is known to be associated with the efflux pump, PmrA. However, there may be other efflux systems that also cause drug resistance. Two types of mutants were studied. The efflux phenotype from mutants selected by sub-MIC levofloxacin or gemifloxacin was transformed into R6. These transformants did not show increased pmrA transcripts in Northern blots; insertional inactivation of pmrA in the transformants did not abolish the efflux phenotype. A second set of efflux phenotype mutants was selected in R6:cat by ethidium bromide but not by norfloxacin; accumulation of ethidium bromide in the one among these mutants studied was reduced in comparison to its parent. This evidence suggests that systems other than PmrA can contribute to efflux-mediated resistance in pneumococci.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588335     DOI: 10.1046/j.1469-0691.2003.00482.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  9 in total

1.  Fluoroquinolone efflux in Streptococcus suis is mediated by SatAB and not by SmrA.

Authors:  Jose Antonio Escudero; Alvaro San Millan; Belen Gutierrez; Laura Hidalgo; Roberto M La Ragione; Manal AbuOun; Marc Galimand; María José Ferrándiz; Lucas Domínguez; Adela G de la Campa; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin.

Authors:  Estelle Marrer; A Tatsuo Satoh; Margaret M Johnson; Laura J V Piddock; Malcolm G P Page
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae.

Authors:  Estelle Marrer; Karen Schad; Andreas T Satoh; Malcolm G P Page; Maggie M Johnson; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

5.  Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.

Authors:  Mark I Garvey; Alison J Baylay; Ryan L Wong; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

6.  The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.

Authors:  Mark I Garvey; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

7.  The biofilm inhibitor Carolacton inhibits planktonic growth of virulent pneumococci via a conserved target.

Authors:  Jannik Donner; Michael Reck; Simone Bergmann; Andreas Kirschning; Rolf Müller; Irene Wagner-Döbler
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

8.  Whole Genome Sequencing of 39 Invasive Streptococcus pneumoniae Sequence Type 199 Isolates Revealed Switches from Serotype 19A to 15B.

Authors:  Oliwia Makarewicz; Marie Lucas; Christian Brandt; Leonie Herrmann; Andreas Albersmeier; Christian Rückert; Jochen Blom; Alexander Goesmann; Mark van der Linden; Jörn Kalinowski; Mathias W Pletz
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

9.  Upregulation of the PatAB Transporter Confers Fluoroquinolone Resistance to Streptococcus pseudopneumoniae.

Authors:  María Alvarado; Antonio J Martín-Galiano; María J Ferrándiz; Ángel Zaballos; Adela G de la Campa
Journal:  Front Microbiol       Date:  2017-10-26       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.